Listeria Rhombencephalitis Complicating Anti-TNF Treatment during an Acute Flare of Crohn’s Colitis by L. Stratton, G. R. Caddy

“…Such medication includes steroids, azathioprine, and biologic therapy. These suppress the immune response, and the patient is more susceptible to infection. …”
Get full text

Colonic strictures in Crohn’s disease: a non-surgical survival by Sarra Laabidi, Hamed Aboubecrine, Salma Souissi, Donia Gouiaa, Asma Labidi, Nadia Ben Mustapha, Anis Haddad, Amine Sebai, Meriem Serghini, Monia Fekih, Hanene Jaziri, Jalel Boubaker

“…In multivariate analysis, biologic therapy was the only independent protective factor against surgery (p = 0.001, OR = 0.19).Conclusion The early introduction of biologic therapy is crucial for increasing surgery-free survival in patients with colonic stenosis in CD, given the limited effectiveness of conventional treatments.…”
Get full text

Dual Biologic or Small Molecule Therapy in Pediatric Inflammatory Bowel Disease: A Single Center Experience by Cheng Guo, Jin Zhou, Guoli Wang, Jie Wu

“…The purpose of this study was to evaluate the efficacy and safety of dual biologic therapy or biologics combined with small molecule drugs in refractory PIBD patients in China. …”
Get full text

Use of biologic response modifiers for the management of ocular inflammatory conditions by Erick Rivera-Grana, Jay Siak, James T Rosenbaum

“…These cases highlight the considerations that are required when clinicians are faced with the need to commence biologic therapy for patients with refractory ocular inflammation.…”
Get full text

Sulfasalzine in the management of pure axial spondyloarthritis: Need to have a relook! by Subramanian Shankar, Arun Hegde

“…Guidelines recommend early institution of biologic therapy if one fails 2 NSAIDs sequentially in optimal doses over 4 weeks. …”
Get full text

Liver Injury Secondary to Anti-TNF-Alpha Therapy in Inflammatory Bowel Disease: A Case Series and Review of the Literature by Ravish Parekh, Nirmal Kaur

“…Background. Biologic therapy to inhibit tumor necrosis factor-alpha (TNF-α) is an effective, safe treatment for patients with inflammatory bowel disease (IBD). …”
Get full text

Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn’s Disease by Sue Perera, Shibing Yang, Marni Stott-Miller, Joanne Brady

“…**Background:** This retrospective cohort study aimed to describe and quantify healthcare resource utilization and costs for patients with ulcerative colitis (UC) and Crohn’s disease (CD) following initiation of biologic therapy. **Methods:** Resource utilization and costs were analyzed at baseline and 1- and 2-years after initiating a biologic. …”
Get full text

Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? by Andrea Cassoni, Umberto Romeo, Valentina Terenzi, Marco Della Monaca, Oriana Rajabtork Zadeh, Ingrid Raponi, Maria Teresa Fadda, Antonella Polimeni, Valentino Valentini

“…The authors suggest that the biologic therapy with an anti-TNF-α antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity of the bone.…”
Get full text

Treatment of Extensive Plaque Psoriasis and Psoriatic Arthropathy using Methotrexate in a Patient with High Serum Alkaline Phosphatase by Suad HH, Muna Mohammed El Amin, Gad Allah Modawe, Osman Elbasheer

“…There are many treatment options, but the severe forms of psoriasis are treated successfully with cytotoxic and biologic therapies. Methotrexate being cheap and available in Sudan is considered a good option for patients with severe and extensive forms of psoriasis. …”
Get full text

Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps by Shaun J. Kilty, Andrea Lasso

“…This study aims to assess how clinical outcomes of biologic therapy in real-world application (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness gap. …”
Get full text

Dexamethasone in Treatment of Comorbid SARS-CoV-2 Patients Aged over 50 Years with Lung Injury over 50 % by O. Yu. Zolnikova, R. V. Maslennikov, V. T. Ivashkin, N. L. Dzhakhaya, O. Yu. Kiseleva, N. D. Potskhverashvili, S. A. Shorokhova

“…A retrospective study of 158 SARS-CoV-2 patients hospitalised in April—June 2020 was conducted under the inclusion criteria: age over 50 years, chest computed tomography (CT) for COVID-19-asso-ciated pneumonia, C-reactive protein (CRP) >50 mg/L, anticoagulant therapy, no contraindications to steroids, no biologic therapy. Cohort 1 patients (n = 96) received dexamethasone 4–12 mg/day, cohort 2 (n = 62) — a standard non-dexamethasone therapy.Results. …”
Get full text

Real-World Health Care Outcomes and Costs Among Patients With Juvenile Idiopathic Arthritis in Spain by Jordi Antón, Estefania Moreno Ruzafa, Mireia Lopez Corbeto, Rosa Bou, Judith Sánchez Manubens, Sonia Carriquí Arenas, Joan Calzada Hernández, Violetta Bittermann, Carolina Estepa Guillén, Juan Mosquera Angarita, Lucía Rodríguez Díez, Estíbaliz Iglesias, Miguel Marti Masanet, Berta Lopez Montesinos, Maria I. González Fernández, Alfonso de Lossada, Carmen Peral, Mónica Valderrama, Noelia Llevat, María Montoro Álvarez, Immaculada Calvo Penadés

“…Average cost of pharmacological treatment was €3021.80 (€3956.20), mainly due to biologic therapy €2789.00 (€3399.80). Direct annual cost (excluding treatments) was €3654.60 (€3899.00). …”
Get full text

Case Report: Combined Autoimmune Pancreatitis, Ulcerative Colitis and Sclerosing Cholangitis in 28-y.o. Patient by A. R. Khurmatullina, A. V. Okhlobystin, L. N. Androsova, R. T. Rzayev, A. S. Tertychnyy, A. P. Kiryukhin, O. Z. Okhlobystina, M. S. Zharkova, O. S. Shifrin, V. T. Ivashkin

“…The patient was recommended to receive biologic therapy for UC remission induction.Conclusion. …”
Get full text

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease by Panu Wetwittayakhlang, Farah Albader, Petra A Golovics, Gustavo Drügg Hahn, Talat Bessissow, Alain Bitton, Waqqas Afif, Gary Wild, Peter L Lakatos

“…A flare of IBD post-COVID-19 infection was reported in 8 patients (9.8%) within 3 months. Biologic therapy was held during active COVID-19 infection in 37% of patients. …”
Get full text

New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy by Claudia Fabiani, Jurgen Sota, Maite Sainz-de-la-Maza, Laura Pelegrín, Giacomo Emmi, Giuseppe Lopalco, Florenzo Iannone, Lorenzo Vannozzi, Silvana Guerriero, Maria Chiara Gelmi, Donato Rigante, Gian Marco Tosi, José Hernández-Rodríguez, Luca Cantarini

“…Scleritis relapses significantly decreased between the 12 months preceding and following biologic therapy (p=0.007). No differences regarding BCVA were observed (p=0.67). …”
Get full text

Long-Term Follow-Up, Association between CARD15/NOD2 Polymorphisms, and Clinical Disease Behavior in Crohn’s Disease Surgical Patients by Francesco Giudici, Tiziana Cavalli, Cristina Luceri, Edda Russo, Daniela Zambonin, Stefano Scaringi, Ferdinando Ficari, Marilena Fazi, Amedeo Amedei, Francesco Tonelli, Cecilia Malentacchi

“…Patients carrying an hz881 and a 3020insC exhibited, respectively, a lower rate of responsiveness to azathioprine (p=0.012), but no difference was found in biologic therapy. Finally, the risk of surgical recurrence was significantly associated, respectively, to age at diagnosis, to familial CD history, to diagnostic delay, to arthritis, and to the presence of perioperative complications. …”
Get full text

Evaluation of host immune responses to Mycobacteriophage Fionnbharth by route of delivery by Thomas Smytheman, Tiffany Pecor, Dana E. Miller, Debora Ferede, Suhavi Kaur, Matthew H. Harband, Hazem F. M. Abdelaal, Carlos A. Guerrero-Bustamante, Krista G. Freeman, Whitney E. Harrington, Lisa M. Frenkel, Graham F. Hatfull, Rhea N. Coler, Sasha E. Larsen

“…Mycobacteriophages (phages) are a sorely underutilized biologic therapy for the pathogen M.tb, and here we aimed to address outstanding questions about their utility for clinical applications. …”
Get full text

Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT) by Ramtin Lichtenberger, Lara Valeska Maul, Ion Birkenmaier, Iker Oyanguren, Melike Ak, Kristine Heidemeyer, Christoph Schlapbach, Nikhil Yawalkar, Alexander Egeberg, Simon Francis Thomsen, Jacob P. Thyssen, Christina Sorbe, Wolf-Henning Boehncke, Curdin Conrad, Antonio Cozzio, Georgios Kokolakis, Raphael Micheroli, Jashin J. Wu, Thomas Kündig, Alexander Navarini, Julia-Tatjana Maul

“…These findings emphasize that women with psoriasis experience lower quality of life at treatment initiation and throughout non-biologic and biologic therapies, underlining the importance of addressing gender-specific differences in the management of psoriasis. …”
Get full text

Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA... by Carla Gaggiano, Antonio Vitale, Laura Obici, Giampaolo Merlini, Alessandra Soriano, Ombretta Viapiana, Marco Cattalini, Maria Cristina Maggio, Giuseppe Lopalco, Davide Montin, Masen Abdel Jaber, Lorenzo Dagna, Raffaele Manna, Antonella Insalaco, Matteo Piga, Francesco La Torre, Virginia Berlengiero, Viviana Gelardi, Luisa Ciarcia, Giacomo Emmi, Piero Ruscitti, Francesco Caso, Rolando Cimaz, José Hernández-Rodríguez, Paola Parronchi, Ludovico Luca Sicignano, Elena Verrecchia, Florenzo Iannone, Jurgen Sota, Salvatore Grosso, Carlo Salvarani, Bruno Frediani, Roberto Giacomelli, Maria Antonietta Mencarelli, Alessandra Renieri, Donato Rigante, Luca Cantarini

“…Biologic agents were prescribed to 49 (61%) patients; R92Q subjects were more frequently on NSAIDs monotherapy than other patients (p<0.01); nevertheless, they required biologic therapy in 53.1% of cases. At disease onset, the latest classification criteria for TRAPS were fulfilled by 64/80 (80%) patients (clinical plus genetic items) and 46/80 (57.5%) patients (clinical items only). …”
Get full text

Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis by A. O. Golovenko, I. L. Khalif, O. V. Golovenko, V. V. Veselov

“…Aim of investigation. Biological therapy by monoclonal antibodies against tumor necrosis factor (infliximab) allows to avoid colectomy at steroid-resistant severe attack of ulcerative colitis. …”
Get full text